How Close are We to a Readily available, Clinically Reliable Blood Test for Alzheimer's disease?

Abstract

Neurodegenerative Disease ManagementVol. 3, No. 5 EditorialHow close are we to a readily available, clinically reliable blood test for Alzheimer’s disease?Pedro Pesini & Manuel SarasaPedro PesiniAraclon Biotech Ltd, Vía Hispanidad 21, 50009 Zaragoza, SpainSearch for more papers by this author & Manuel Sarasa* Author for correspondenceAraclon Biotech Ltd, Vía Hispanidad 21, 50009 Zaragoza, Spain. Search for more papers by this authorEmail the corresponding author at msarasa@araclon.comPublished Online:16 Sep 2013https://doi.org/10.2217/nmt.13.48AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleReferences1 Alzheimer’s Disease International. World Alzheimer Report 2010. Alzheimer’s Disease International, London, UK (2010).Google Scholar2 Jack CR Jr, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol.9(1),119–128 (2010).Crossref, Medline, CAS, Google Scholar3 Villemagne VL, Burnham S, Bourgeat P et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol.12,357–367 (2013).Crossref, Medline, CAS, Google Scholar4 Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement.7(3),280–292 (2011).Crossref, Medline, Google Scholar5 Jack CR Jr, Knopman DS, Weigand SD et al. An operational approach to National Institute on Aging – Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann. Neurol.71(6),765–775 (2012).Crossref, Medline, Google Scholar6 Petersen RC, Aisen P, Boeve BF et al. Criteria for mild cognitive impairment due to alzheimer’s disease in the community. Ann. Neurol. doi:10.1002/ana.23931 (2013) (Epub ahead of print).Google Scholar7 Henriksen K, O’Bryant SE, Hampel H et al. The future of blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement. doi:10.1016/j.jalz.2013.01.013 (2013) (Epub ahead of print).Medline, Google Scholar8 Pérez-Grijalba V, Pesini P, Monleón I et al. Several direct and calculated biomarkers from the amyloid-beta pool in blood are associated with an increased likelihood of suffering from mild cognitive impairment. J. Alzheimers Dis.36,211–219 (2013).Crossref, Medline, CAS, Google Scholar9 Toledo JB, Vanderstichele H, Figurski M et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol.122(4),401–413 (2011).Crossref, Medline, CAS, Google Scholar10 Yaffe K, Weston A, Graff-Radford NR et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA305(3),261–266 (2011).Crossref, Medline, CAS, Google Scholar11 Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F. Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch. Neurol.69(7),824–831 (2012).Crossref, Medline, Google Scholar12 Sarasa L, Allué J, Pesini P, Sarasa M. Identification of β-amyloid species in canine CSF by mass spectrometry. Neurobiol. Aging34,2125–2132 (2013).Crossref, Medline, CAS, Google Scholar13 Pérez-Grijalva V, Sarasa L, Allué JA et al. Aβ 17 is a major Aβ fragment isoform in CSF and blood with diagnostic value. Alzheimers Dement.8(4),P240 (2013).Crossref, Google Scholar14 Kuo YM, Kokjohn TA, Kalback W et al. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem. Biophys. Res. Commun.268(3),750–756 (2000).Crossref, Medline, CAS, Google Scholar15 Rogers J, Li R, Mastroeni D et al. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol. Aging27(12),1733–1739 (2006).Crossref, Medline, CAS, Google Scholar16 Becan-McBride K. Laboratory sampling. Does the process affect the outcome? J. Intraven. Nurs.22(3),137–142 (1999).Medline, CAS, Google Scholar17 DeMeyer G, Shapiro F, Vanderstichele H et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol.67(8),949–956 (2010).Crossref, Medline, Google Scholar18 Foster N, King R, Wang A et al. Diagnostic classification with amyloid PET and FDG-PET among clinically diagnosed Alzheimer’s disease patients in the Alzheimer’s disease neuroimaging initiative. Hum. Amyloid Imaging Abstract (2012).Google Scholar19 Cummings JL, Dubois B, Molinuevo JL, Scheltens P. International Work Group criteria for the diagnosis of Alzheimer disease. Med. Clin. North Am.97(3),363–368 (2013).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 3, No. 5 Follow us on social media for the latest updates Metrics Downloaded 17 times History Published online 16 September 2013 Published in print October 2013 Information© Future Medicine LtdFinancial & competing interests disclosureM Sarasa is the scientific founder of Araclon Biotech Ltd and its current President, CEO and CSO, and P Pesini is its research and development director. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download